查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球系统性红斑狼疮市场
市场调查报告书
商品编码
1279681

2023-2030 年全球系统性红斑狼疮市场

Global Systemic Lupus Erythematosus Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球系统性红斑狼疮市场预计将实现利润丰厚的增长，到 2022 年将达到 18.932 亿美元，到 2030 年将达到 32.957 亿美元。 系统性红斑狼疮市场预计在预测期内（2023-2030 年）的复合年增长率为 7.3%。

系统性红斑狼疮 (SLE) 是一种慢性自身免疫性疾病，免疫系统错误地攻击健康组织，对皮肤、关节、肾臟、心臟、肺、大脑等造成伤害。你可能会。 SLE 在女性中更为常见，通常发生在 25 至 45 岁之间。

它会导致慢性炎症和各种症状，并可能降低人的生活质量。 全球系统性红斑狼疮市场预计在未来几年将显着增长，原因是对该疾病的了解增加、诊断率提高以及新疗法的发现。

市场动态

政府举措的增加有望推动全球系统性红斑狼疮市场的增长

世界各国政府正在努力改善 SLE 治疗的可及性和治疗方法，增加研发资金，并促进监管以改善患者预后。是。

例如，根据美国疾病控制与预防中心 (CDC) 2022 报告，CDC-RFA-DP20-2008 是一个为期五年的合作物。 该合作协议的基本目标是支持国家组织并与国家组织建立伙伴关係，以提高国家对狼疮的认识和能力。

该协议旨在增加能够识别狼疮体征并在检测到时做出适当反应的医护人员的数量。 此外，该协议旨在增加狼疮患者对自我管理工具和服务的参与，从而使患者的自我管理行为发生积极变化。 因此，上述因素预计将在预测期内推动全球系统性红斑狼疮市场的增长。

全球系统性红斑狼疮市场可能面临治疗副作用的限制

许多现有的 SLE 药物具有潜在的严重副作用，可能会阻止患者使用它们。 患者不愿采用具有显着副作用的疗法可能是一个重要的市场限制。

泼尼松是皮质类固醇的一个例子，它可以帮助减轻炎症和缓解关节疼痛和皮疹等症状，但它也可能有严重的副作用，例如体重增加、高血压和骨质疏鬆症。

COVID-19 影响分析

随着 COVID-19 的流行，系统性红斑狼疮 (SLE) 对全球市场产生了重大影响。 限制患者获得医疗保健是大流行的重大影响之一。 许多系统性红斑狼疮患者的免疫系统较弱，更有可能发展为严重的 COVID-19，导致医疗关注减少以及识别和治疗延误。

这会对患者的治疗结果产生负面影响。 COVID-19 疫情阻碍了 SLE 药物进入市场，导致患者和医疗保健系统出现短缺和价格上涨。

俄乌衝突分析

俄罗斯和乌克兰之间的衝突可能会对全球系统性红斑狼疮 (SLE) 市场产生意想不到的后果，尤其是 SLE 药物的供应链。 乌克兰正在成为一个重要的製药商，并向其他国家出口药品。 如果生产设施或运输路线因战争而被毁坏或关闭，可能会影响 SLE 药物的供应链。

此外，由于衝突，当地医疗保健基础设施和可及性可能会下降，导致乌克兰及周边地区的系统性红斑狼疮 (SLE) 患者等待诊断和治疗的时间很长。 然而，系统性红斑狼疮的全球市场是多样化的，药物供应并不严重依赖于任何特定的地区或国家。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按药物类别分类的片段
  • 按投放方式分类的摘要
  • 按销售渠道
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 预计政府举措的增加将推动全球系统性红斑狼疮市场
    • 约束因素
      • 全球系统性红斑狼疮市场可能面临治疗特异性副作用的限制
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法律法规分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章药物类别

  • 抗疟药
  • 非甾体抗炎药
  • 细胞毒性/免疫抑製剂
  • 生物製品
  • 其他

第八章交付模式

  • 静脉给药
  • 皮下给药
  • 口语
  • 局部管理

第 9 章分销渠道

  • 零售药房
  • 医院药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第12章公司简介

  • Anthera 製药公司
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Eli Lilly
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Limited
  • Sanofi
  • Lycera Corporation
  • Bristol-Myers Squibb
  • ImmuPharma Plc
  • Merck KGaA

第13章 附录

简介目录
Product Code: PH51

Market Overview

The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.

Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.

Market Dynamics

The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.

Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.

For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.

The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.

The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.

Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.

Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.

COVID-19 Impact Analysis

In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.

This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems.

Russia Ukraine Conflict Analysis

The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.

In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.

Segment Analysis

The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.

The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.

The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.

Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.

Geographical Analysis

North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.

The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.

In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.

Competitive Landscape

The major global players in the market include: Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

Why Purchase the Report?

  • To visualize the global systemic lupus erythematosus- market segmentation based on drug class, mode of delivery, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global systemic lupus erythematosus market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Mode of Delivery
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising number of government initiatives is expected to drive the global systemic lupus erythematosus market.
    • 4.1.2. Restraints
      • 4.1.2.1. The global systemic lupus erythematosus market may face constraints due to adverse effects of treatment.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimalarial Drugs
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-Steroidal Anti-Inflammatory Drugs
  • 7.4. Cytotoxic And Immunosuppressive Drugs
  • 7.5. Biologics
  • 7.6. Others

8. By Mode of Delivery

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 8.1.2. Market Attractiveness Index, By Mode of Delivery
  • 8.2. Intravenous
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Subcutaneous
  • 8.4. Oral
  • 8.5. Topical

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Retail Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Anthera Pharmaceuticals Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Eli Lilly
  • 12.3. GlaxoSmithKline Plc
  • 12.4. F. Hoffmann-La Roche Ltd
  • 12.5. Pfizer Limited
  • 12.6. Sanofi
  • 12.7. Lycera Corporation
  • 12.8. Bristol-Myers Squibb
  • 12.9. ImmuPharma Plc
  • 12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us